PL
KPTI icon

Parkwood LLC’s Karyopharm Therapeutics KPTI Stock Holding History

Parkwood LLC’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-66,667
Closed -$661K – 151
2023
Q3 		$661K Hold
66,667
– – 0.07% 93
2023
Q2 		$669K Buy
+66,667
New +$2.87M 0.12% 96

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Parkwood LLC's KPTI Position: Q4 2023 in Review

Parkwood LLC sold out of Karyopharm Therapeutics (KPTI) in Q4 2023, closing a stake of 66,667 shares — an estimated $661K sold.

Parkwood LLC first reported a position in KPTI in Q2 2023 and held it in 2 quarters. The position peaked at $669K in Q2 2023. 117 funds tracked by Wall St. Rank hold KPTI as of Q4 2023.

  • Parkwood LLC reported no remaining Karyopharm Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Parkwood LLC sold 66,667 Karyopharm Therapeutics shares in Q4 2023, an estimated $661K.
  • Parkwood LLC first reported a position in Karyopharm Therapeutics in Q2 2023 and held it in 2 quarters.
  • Parkwood LLC's Karyopharm Therapeutics position peaked at $669K in Q2 2023.
  • 117 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2023.

Based on Parkwood LLC's 13F filing for Q4 2023, filed 14 Feb 2024.